Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Pharmalot
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Celgene just lost a crucial drug for its revenue stream after a clinical trial blowup

  • Adam Feuerstein

By Adam Feuerstein Oct. 19, 2017

Reprints
Celgene
Kristoffer Tripplaar/SIPA via AP

Celgene just lost one of the most important drugs in its research pipeline to a late-stage clinical trial blowup.

The drug is mongersen, a key component in Celgene’s burgeoning immunology and inflammation franchise. On Thursday, a phase 3 study of mongersen in Crohn’s disease was halted prematurely following a finding of clinical futility by independent monitors, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
The lesson biotech absolutely should not take from Silicon…
The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
Senators interrogate health secretary Becerra on Alzheimer’s drug coverage
89bio treatment reduces liver scarring in patients with NASH,…
89bio treatment reduces liver scarring in patients with NASH, meeting study goals

Comments are closed.

Recommended Stories